DOMINGUEZ, Luis Carlos; SANABRIA, Álvaro Enrique; VEGA, Neil Valentín    OSORIO, Camilo. Are somatostatin and its analogues (octreotide and lanreotide) useful in the management of patients with enterocutaneous fistulae?: Systematic literature review. []. , 25, 3, pp.202-211. ISSN 2011-7582.

Introduction. Enterocutaneous fistulae constitute an infrequent but catastrophic complication in the surgical patient. Somatostatin and its analogues (octeotide and lanreotide) are frequently indicated in the management of these fistulae, but variable results have been reported in published clinical experiments. The aim of this study was to evaluate the efficacy of somatostatin and its analogues in the management of enterocutaneous fistulae. Methods. Systematic review of published clinical experiments comparing somatostatin and its analogues wth placebo or other therapeutic modalities in patients with enterocutaneous fistulae. Analysis of quality was made according to the Cochrane Collaboration recommendations. Primary results were: rate of closure, time until closure and reduction of output; secondary results were: morbidity, mortality, length of hospital stay, costs, and quality of life. Results. Eight studies were identified, 172 patients managed with somatostatin or its analogues and 134 patients with placebo or other treatment modalities. Methodologically the studies appear of low quality. Average elapsed time to closure was 10 days with somatostin or its analogues and the closure rate was superior as compared with placebo. Somatostain plus total parenteral nutrition demonstrated the highest clinical efficacy (85%). In manner statistically significant, the output of the fistulae diminished with the use of somatostatin or its analogues. Mortality and morbidity results were variable. There is no information on quality of life. Conclusions. Somatostain and its analogues can be utilized in the management of patients with enterocutaneous fistulae within the first ten days of presentation; however, the information on efficacy appears heterogenous in the different studies that were reviewed. The profile of pharmacological safety in patients with enterocutaneous fistulae should be evaluated in complementary studies..

: somatostatin; octreotide; fistula; intestinal fistula.

        · |     · |     · ( pdf )